Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

af Pistilli, B., Pluard, T., Urruticoechea, A., Farci, D., Kong, A., Bachelot, T., Chan, S., Han, H. S., Jerusalem, G., Urban, P., Robinson, D., Mouhaër, S. L., Tomaso, E. D., Massacesi, C., Saura, C.
Udgivet i Breast Cancer Res Treat (2017)